Best Options Strategy for ZLAB
Looking for the best options strategy for Zai Lab Limited (ZLAB)? There is no single answer — the right play depends on your outlook, your risk tolerance and current implied volatility. Below, our free engine shows the highest-scoring defined-risk strategy on the live ZLAB option chain right now, and a simple map from your view on ZLAB to the strategy that fits it. Model any of them in the calculator before you trade.
About ZLAB
Zai Lab Limited (ZLAB) is a major company in Biotechnology. Options traders on ZLAB tend to watch , since these can drive large moves in the share price.
About Zai Lab Limited
Zai Lab is a Chinese biopharmaceutical company that discovers, develops, and sells medicines targeting oncology, immunology, neuroscience, and infectious disease. Its marketed portfolio includes several FDA-approved or internationally licensed drugs: Zejula, a PARP inhibitor for ovarian cancer; VYVGART, an antibody fragment for neuromuscular disorders like myasthenia gravis; NUZYRA for bacterial pneumonia and skin infections; Optune for brain tumors; Qinlock for gastrointestinal stromal tumors; Xacduro for hospital-acquired pneumonia; and Augtyro for certain lung cancers. The company operates through partnerships with major pharmaceutical and biotech firms including Pfizer, Amgen, Boehringer Ingelheim, NovoCure, and several others, leveraging these relationships to expand its drug pipeline and market reach.
The company generates revenue by commercializing its approved medicines across multiple therapeutic areas, primarily in oncology and infectious disease markets. Its financial model relies on product sales from its marketed drugs combined with milestone payments and royalties from its network of strategic collaborations. Founded in 2013 and headquartered in Shanghai's Pudong…
Today's top-scoring strategy for ZLAB
Our engine ranks defined-risk strategies on the live ZLAB chain by probability of profit and risk/reward, then surfaces the best-scoring one. It is an educational illustration, not advice.
| Action | Qty | Type | Strike | Premium |
|---|---|---|---|---|
| Buy | 1× | PUT | $17 | $0.03 |
| Sell | 1× | PUT | $18 | $0.15 |
| Sell | 1× | CALL | $20 | $0.12 |
| Buy | 1× | CALL | $21 | $0.02 |
Simulation
Forward simulation of 6,000 lognormal price paths to expiration — not a historical backtest.
Illustrative example at ZLAB's latest available price, computed with the same engine as the tool. Live option fills and the real IV skew refresh during US market hours.
Implied volatility
ZLAB is currently trading with moderate implied volatility, broadly in line with other large-cap stocks. On the options we scanned that was around 32% implied volatility, and higher implied volatility means richer premiums and wider expected moves.
Options on ZLAB currently price in about 32% implied volatility, versus roughly 35% the stock has actually realised over the past month. The two are roughly in line, so neither buying nor selling premium has a clear volatility edge here.
Off that volatility, the options market is pricing a move of about ±$1.2 (±6%) in ZLAB by 2026-07-17 — a range of roughly $17.72 to $20.12. Strikes inside that band hold most of the premium and see most of the action.
Across strikes, downside puts on ZLAB trade at a higher implied volatility than upside calls — the market is paying up for crash protection. That skew favours selling put spreads or buying calls over symmetric trades.
Earnings & IV crush
ZLAB's next earnings report is due around August 6, 2026. Options that expire after it price in a binary move, so their implied volatility is elevated and usually collapses right after the announcement — an "IV crush". If your expiration falls before this date, the trade sidesteps the event.
Key figures
- Market cap
- $2.2B
- Beta (vs market)
- 0.78
- 52-week range
- $15.96–$41.20 (12% up the range)
- Short interest
- 6.6% of float · 7.5 days to cover
How to choose an options strategy for ZLAB
Start with your outlook on ZLAB, then match it to a defined-risk structure. Here are the most common choices and when each makes sense:
Bullish
Buy a call for leverage with capped risk, or a bull call spread to lower the cost and breakeven when you have a target price.
Long Call → Bull Call Spread →Bearish
Buy a put to profit from a decline with defined risk, or a bear put spread to cheapen the trade when you expect a measured move down.
Long Put → Bear Put Spread →Neutral
Sell an iron condor to collect premium while ZLAB stays between two strikes, or write a covered call against shares you already own.
Iron Condor → Covered Call →How we pick the best strategy
For each ticker we pull the live option chain, build every supported strategy around the at-the-money strikes, and score them on probability of profit, risk/reward and capital efficiency — favouring defined-risk structures where the maximum loss is known up front. Methodology →
Open ZLAB in the free calculator →
Frequently asked questions
What is the best options strategy for ZLAB?
It depends on your outlook. Bullish traders often use a long call or bull call spread on ZLAB; bearish traders a long put or bear put spread; neutral traders an iron condor or covered call. Our live scan above shows the current highest-scoring defined-risk play.
Are ZLAB options liquid enough to trade?
Zai Lab Limited (ZLAB) is among the most actively-traded US options, which usually means tight bid/ask spreads and plenty of strikes and expirations — though you should always check the open interest and spread on the exact contract.
How much money do I need to trade ZLAB options?
Buying a single ZLAB call or put can cost as little as the premium (often one to a few hundred dollars), while income strategies like a cash-secured put need enough capital to buy 100 shares if assigned.
Is this financial advice?
No. Everything here is educational and uses delayed, third-party data. It is not a recommendation to trade ZLAB or any security. Do your own research.
What does Zai Lab Limited do?
Zai Lab Limited (ZLAB) operates in the Biotechnology industry. The "About Zai Lab Limited" section above gives a fuller picture of what the company does and how it earns money.
Does Zai Lab Limited pay a dividend?
Zai Lab Limited does not currently pay a dividend, so there is no ex-dividend assignment risk to plan around for options strategies.
When does Zai Lab Limited next report earnings?
Zai Lab Limited's next earnings are expected around August 6, 2026. Implied volatility usually climbs into the report and drops sharply afterwards (IV crush) — important for any options position held over the date.
Tickers related to ZLAB
Comparing ZLAB with similar names can help you choose the best options strategy:
Company information
- Headquarters
- Building B, 899 Halei Road, Pudong, 201203, China
- Industry
- Biotechnology
- Employees
- 1,784
- CEO
- Dr. Ying Du Ph.D.
- Phone
- 86 21 6163 2588
- Website
- www.zailaboratory.com
Best Options Strategy by Ticker →
Educational use only. Quotes are delayed ~15 minutes and nothing here is financial advice. Options trading involves substantial risk of loss. Privacy · Terms.